Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enicepatide + petrelintide
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Enicepatide + petrelintide is an investigational fixed-dose combination of two once-weekly subcutaneous peptide drugs being developed by Roche, in collaboration with Zealand Pharma, for chronic weight management in adults with obesity or overweight. The combination consists of enicepatide (formerly CT-388), a cAMP signal-biased dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist, and petrelintide, a long-acting human amylin receptor agonist. By combining incretin receptor dual agonism with amylin receptor agonism, the therapy aims to achieve enhanced weight loss efficacy through complementary satiety and metabolic pathways while maintaining a favorable gastrointestinal tolerability profile. The combination is being evaluated in the Phase II ZYNERGY dose-finding clinical trial.
- Other names
- CT-388 + petrelintideenicepatide/petrelintidepetrelintide + enicepatidepetrelintide/enicepatide
02
Targets
AMY (Pancreatic alpha-amylase)AMY3 (Amylin receptor 3)CALCR (Calcitonin receptor)GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)RAMP1 (Receptor activity-modifying protein 1)RAMP3 (Receptor activity-modifying protein 3)
Beyond the preview
Go deeper on enicepatide + petrelintide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enicepatide + petrelintide.